Share This

Hot News

和黃醫藥今日起招股每股發售價最高45元- RTHK @ 2021-06-19T12: Back Hot News
Keyword:新股 和黃醫藥 招股
Concept:和黃醫藥入場費 , 招股首日孖展
長和 (00001)旗下生物科技公司和黃醫藥 (新上市編號:00013)周五(18日)起招股,並披上原本和黃00013的號碼。綜合多間券商數據,和黃醫藥孖展錄得3億元,暫未足額認購。當中,華盛證券借出5000萬元,輝立借出4000萬元。
同日起招股的和黃醫藥(00013)表現較為遜色,孖展認購未足額。該公司將於下周三(23日)截止認購,計劃發售約1.04億股股份,招股價45元,每手500股,入場費為22,726.74元,預計於6月30日上市。
【新股IPO】和黃醫藥13今日起招股 一手入場費為22727元
內地茶飲品牌奈雪的茶及長和旗下的和黃醫藥緊接招股,券商預留大額孖展。
奈雪的茶(02150)及和黃醫藥(00013)同日招股,惟市場反應兩極。奈雪的茶反應熱烈,首日已錄得715億元孖展,超購131倍。相反和黃醫藥僅錄約2億元孖展認購,暫未足額認購。越秀服務(06626)昨日孖展截飛,反應一般,錄7.9億元孖展超購2倍。分析認為,奈雪的茶認購反應熾熱,相信可引起短期炒作,惟業務仍然虧損,利潤率低,不建議長期持有。
同日開招的還有來港第二上市的和黃醫藥(013),惟招股反應慢熱,暫錄1.13億元孖展額認購,仍未足額認購。和黃醫藥以500股為一手,每股發售價最高45元,入場門檻達22,727元左右,和黃醫藥的美股周四收報28.36美元,每份ADR代表5股計,折合約44.038港元,因此最高定價45元暫時存在溢價問題。
另外,奈雪的茶(02150)及和黃中國醫藥(00013)周五開始招股,他建議投資者可先觀望認購反應,才決定是否認購,及用孖展抑或現金認購。若然認購反應非常熱烈,要提防未能抽中而蝕息蝕使費的風險,即使分貨不足,亦可考慮在新股暗盤買入,都有獲利機會。

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.